This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sahloff, E. G. Articles by Martin, S. J. Search for Related Content Social Bookmarking                         What's this?

Extended-Spectrum β-Lactamase Resistance in the ICU

Department of Pharmacy Practice, The University of Toledo, College of Pharmacy, 2801 West Bancroft Street, Toledo, OH 43606, esahloff{at}yahoo.com

Steven J. Martin, PharmD, BCPS

Infectious Disease Research Laboratory, Department of Pharmacy Practice, The University of Toledo, College of Pharmacy, 2801 West Bancroft Street, Toledo, OH 43606, smartin2{at}utnet.utoledo.edu

Despite the recent focus on gram-positive infections in the intensive care unit (ICU), gram-negative resistance mechanisms continue to challenge the critical care practitioner. A recent national surveillance study of United States ICUs found Escherichia coli, Enterbacter species, Klebsiella species, and Pseudomonas aeruginosa represented 72% of all gram-negative bacilli recovered. E coli, Klebsiella pneumoniae, and Enterobacter species are significant producers of a β-lactamase that inactivates almost all β-lactam antibiotics, so-called extended-spectrum β-lactamases or ESBLs. Many clinical laboratories may not test for ESBL-production in these organisms, thus clinicians may be unaware of the rising incidence of this plasmid-mediated resistance mechanism. Since initial reports of ESBLs in the 1980s, investigators have found an association with ESBL-producing organisms and the critically ill population. Risk factors for ESBL-related infection in the ICU include arterial, central-venous, and urinary-catheters; mechanical ventilation; abdominal surgery; prior antibiotic therapy with ceftazidime or other extended spectrum cephalosporins; length of time in the ICU; and overall acuity of illness. This article reviews the emergence and epidemiology of the ESBL evolution, describes the clinical implications of ESBL production in the ICU, and outlines a strategy for management of infection in patients at risk for ESBL-producing organisms.

Key Words: ESBLs (extended spectrum β-lactamases) • antibiotic resistance • third-generation cephalosporins

Journal of Pharmacy Practice, Vol. 15, No. 2, 96-105 (2002)
DOI: 10.1106/VHHD-NGUH-F5T1


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?